clonidine has been researched along with Allodynia in 68 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This double-blind randomized controlled study was designed to evaluate the analgesic effects of topical treatments with clonidine (CLON) and pentoxifylline (PTX) tested alone or as low- and high-dose combinations in a human experimental model of pain." | 9.22 | Effects of topical combinations of clonidine and pentoxifylline on capsaicin-induced allodynia and postcapsaicin tourniquet-induced pain in healthy volunteers: a double-blind, randomized, controlled study. ( Bennett, GJ; Bley, K; Coderre, TJ; Gandhi, W; Laferrière, A; Ragavendran, JV; Schweinhardt, P; Ware, MA, 2016) |
| "Clonidine is approved in the US for epidural administration in the treatment of intractable neuropathic cancer pain, but is also administered intrathecally for this indication and both epidurally and intrathecally in the treatment of acute, postoperative pain." | 9.09 | Relative potency of epidural to intrathecal clonidine differs between acute thermal pain and capsaicin-induced allodynia. ( Curry, R; Eisenach, JC; Hood, DD, 2000) |
| "To the extent that the experimental pain conditions used in this study reflect those in patients with acute and chronic pain, these data support the spinal rather than IV injection of clonidine for analgesia." | 9.08 | Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers. ( Curry, R; Eisenach, JC; Hood, DD, 1998) |
| "Sprague-Dawley rats were used to test the analgesic effect of pentazocine and neostigmine using the paw formalin pain model and the incision mechanical allodynia model." | 8.12 | Antinociceptive Effects and Interaction Mechanisms of Intrathecal Pentazocine and Neostigmine in Two Different Pain Models in Rats. ( Bai, X; Guo, J; Huang, H; Ouyang, H; Wu, S; Zhang, K, 2022) |
| "We studied whether peripheral alpha2-adrenergic receptors are involved in the antihyperalgesic effects of oxcarbazepine by examining the effects of yohimbine (selective alpha2-adrenoceptor antagonist), BRL 44408 (selective alpha(2A)-adrenoceptor antagonist), MK-912 (selective alpha2C-adrenoceptor antagonist), and clonidine (alpha2-adrenoceptor agonist) on the antihyperalgesic effect of oxcarbazepine in the rat model of inflammatory pain." | 7.74 | The involvement of peripheral alpha 2-adrenoceptors in the antihyperalgesic effect of oxcarbazepine in a rat model of inflammatory pain. ( Bosković, B; Paranos, SLj; Prostran, MS; Stepanović-Petrović, RM; Tomić, MA; Ugresić, ND; Vucković, SM, 2007) |
| " The concurrent administration of SB203580 reduces the dosage requirements for clonidine, thereby alleviating allodynia without producing undesirable motor or cardiovascular effects." | 5.43 | Clonidine, an alpha-2 adrenoceptor agonist relieves mechanical allodynia in oxaliplatin-induced neuropathic mice; potentiation by spinal p38 MAPK inhibition without motor dysfunction and hypotension. ( Beitz, AJ; Kim, SJ; Lee, JH; Oh, SB; Roh, DH; Yeo, JH; Yoon, SY, 2016) |
| "Chronic pain is a major health issue and most patients suffer from spontaneous pain." | 5.42 | Huperzine A Alleviates Mechanical Allodynia but Not Spontaneous Pain via Muscarinic Acetylcholine Receptors in Mice. ( Feng, ZH; Li, XY; Liu, L; Mei, SH; Wang, M; Wang, Y; Wang, YJ; Zuo, ZX, 2015) |
| " In the mouse formalin test, DBV injection produced a dramatic leftward shift in the dose-response curve for clonidine-induced analgesia." | 5.35 | Acupoint stimulation with diluted bee venom (apipuncture) potentiates the analgesic effect of intrathecal clonidine in the rodent formalin test and in a neuropathic pain model. ( Beitz, AJ; Han, HJ; Kim, HW; Kwon, YB; Lee, HJ; Lee, JH; Roh, DH; Seo, HS; Yoon, SY, 2009) |
| "CFA injection resulted in significant thermal hyperalgesia throughout the four days of observation." | 5.31 | Intrathecal clonidine decreases spinal nitric oxide release in a rat model of complete Freund's adjuvant induced inflammatory pain. ( Cheng, JT; Chuang, YC; Lin, CR; Wang, CJ; Yang, LC, 2002) |
| "Evidence suggests that the pain and hyperalgesia in SMP are related to activation of peripheral adrenergic receptors." | 5.28 | Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. ( Campbell, JN; Davis, KD; Meyer, RA; Raja, SN; Treede, RD, 1991) |
| "This double-blind randomized controlled study was designed to evaluate the analgesic effects of topical treatments with clonidine (CLON) and pentoxifylline (PTX) tested alone or as low- and high-dose combinations in a human experimental model of pain." | 5.22 | Effects of topical combinations of clonidine and pentoxifylline on capsaicin-induced allodynia and postcapsaicin tourniquet-induced pain in healthy volunteers: a double-blind, randomized, controlled study. ( Bennett, GJ; Bley, K; Coderre, TJ; Gandhi, W; Laferrière, A; Ragavendran, JV; Schweinhardt, P; Ware, MA, 2016) |
| "Clonidine is approved in the US for epidural administration in the treatment of intractable neuropathic cancer pain, but is also administered intrathecally for this indication and both epidurally and intrathecally in the treatment of acute, postoperative pain." | 5.09 | Relative potency of epidural to intrathecal clonidine differs between acute thermal pain and capsaicin-induced allodynia. ( Curry, R; Eisenach, JC; Hood, DD, 2000) |
| "To the extent that the experimental pain conditions used in this study reflect those in patients with acute and chronic pain, these data support the spinal rather than IV injection of clonidine for analgesia." | 5.08 | Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers. ( Curry, R; Eisenach, JC; Hood, DD, 1998) |
| "Sprague-Dawley rats were used to test the analgesic effect of pentazocine and neostigmine using the paw formalin pain model and the incision mechanical allodynia model." | 4.12 | Antinociceptive Effects and Interaction Mechanisms of Intrathecal Pentazocine and Neostigmine in Two Different Pain Models in Rats. ( Bai, X; Guo, J; Huang, H; Ouyang, H; Wu, S; Zhang, K, 2022) |
| " An antiallodynic topical combination of apraclonidine + lisofylline was also found to effectively relieve depressed postocclusive reactive hyperemia in CPIP rats (N = 61) and to increase formazan production in postischemic tissues (skin and muscle) (N = 56)." | 3.80 | Topical combinations to treat microvascular dysfunction of chronic postischemia pain. ( Abaji, R; Coderre, TJ; Laferrière, A; Ragavendran, JV; Tsai, CY, 2014) |
| "Analgesic activity of brimonidine, clonidine, and tizanidine was investigated in wild-type C57B/6, alpha-2A, and alpha-2C knockout mice with allodynia induced by N-methyl-D-aspartate or sulprostone." | 3.75 | Alpha-1-adrenergic receptor agonist activity of clinical alpha-adrenergic receptor agonists interferes with alpha-2-mediated analgesia. ( Cheevers, CV; Donello, JE; Gil, DW; Kedzie, KM; Manlapaz, CA; Rao, S; Tang, E, 2009) |
| "A comparison of total body doses that cause allodynia following spinal or systemic administration indicated that NMDA induces allodynia in the spinal cord while sulprostone and phenylephrine act through a peripheral mechanism." | 3.74 | Transient allodynia pain models in mice for early assessment of analgesic activity. ( Cheevers, CV; Donello, JE; Gil, DW, 2008) |
| "We studied whether peripheral alpha2-adrenergic receptors are involved in the antihyperalgesic effects of oxcarbazepine by examining the effects of yohimbine (selective alpha2-adrenoceptor antagonist), BRL 44408 (selective alpha(2A)-adrenoceptor antagonist), MK-912 (selective alpha2C-adrenoceptor antagonist), and clonidine (alpha2-adrenoceptor agonist) on the antihyperalgesic effect of oxcarbazepine in the rat model of inflammatory pain." | 3.74 | The involvement of peripheral alpha 2-adrenoceptors in the antihyperalgesic effect of oxcarbazepine in a rat model of inflammatory pain. ( Bosković, B; Paranos, SLj; Prostran, MS; Stepanović-Petrović, RM; Tomić, MA; Ugresić, ND; Vucković, SM, 2007) |
| " Intrathecal tizanidine at the dose that reversed hyperalgesia would be preferable for neuropathic pain management because of absence of hypotension and bradycardia and lower incidence of sedation." | 3.72 | Antihyperalgesic and side effects of intrathecal clonidine and tizanidine in a rat model of neuropathic pain. ( Kawamata, T; Namiki, A; Omote, K; Toriyabe, M; Wada, K; Yamamoto, H, 2003) |
| "Chronic pain may be accompanied by hyperalgesia and allodynia, and analgesic interventions may reduce these hypersensitivity phenomena." | 2.80 | Intrathecal clonidine and adenosine: effects on pain and sensory processing in patients with chronic regional pain syndrome. ( Eisenach, JC; North, J; Rauck, RL, 2015) |
| "In contrast, postinfusion pain and hyperalgesia were significantly higher than control." | 2.71 | Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. ( Alsheimer, M; Koppert, W; Scheuber, K; Schmelz, M; Schüttler, J; Sittl, R, 2003) |
| "Mechanical hyperalgesia was measured by von Frey filaments." | 2.71 | The short-lasting analgesia and long-term antihyperalgesic effect of intrathecal clonidine in patients undergoing colonic surgery. ( De Kock, M; Lavand'homme, P; Waterloos, H, 2005) |
| "The prevalences of complex regional pain syndrome, phantom limb pain, chronic donor-site pain, and persistent pain following total joint arthroplasty are alarmingly high." | 2.44 | Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques. ( Buvanendran, A; Reuben, SS, 2007) |
| "Tizanidine was more effective in female than male neuropathic rats." | 1.72 | Sex-dependent antiallodynic effect of α ( Caram-Salas, NL; Castelo-Flores, DG; Centurión, D; De la Luz-Cuellar, YE; Granados-Soto, V; Rodríguez-Palma, EJ; Salinas-Abarca, AB, 2022) |
| " The concurrent administration of SB203580 reduces the dosage requirements for clonidine, thereby alleviating allodynia without producing undesirable motor or cardiovascular effects." | 1.43 | Clonidine, an alpha-2 adrenoceptor agonist relieves mechanical allodynia in oxaliplatin-induced neuropathic mice; potentiation by spinal p38 MAPK inhibition without motor dysfunction and hypotension. ( Beitz, AJ; Kim, SJ; Lee, JH; Oh, SB; Roh, DH; Yeo, JH; Yoon, SY, 2016) |
| "Chronic pain is a major health issue and most patients suffer from spontaneous pain." | 1.42 | Huperzine A Alleviates Mechanical Allodynia but Not Spontaneous Pain via Muscarinic Acetylcholine Receptors in Mice. ( Feng, ZH; Li, XY; Liu, L; Mei, SH; Wang, M; Wang, Y; Wang, YJ; Zuo, ZX, 2015) |
| "Using a rat model of neuropathic pain, we evaluated the effect of pretreatment with clonidine-which has been shown to relieve intradermal capsaicin-induced hyperalgesia-on the initial hyperalgesic response and the thermal analgesic property of RTX." | 1.42 | The effect of clonidine pretreatment on epidural resiniferatoxin in a neuropathic pain rat model. ( Choi, SS; Choi, YS; Huh, BK; Hur, WS; Kim, HS; Kim, HZ; Lee, DK; Lee, MG; Lee, MK; Lim, BG, 2015) |
| "Ankle joint mobilization decreased mechanical hyperalgesia, and this effect was reversed by pretreatment of the animals with caffeine given by intraperitoneal, intraplantar, and intrathecal routes." | 1.39 | Ankle joint mobilization affects postoperative pain through peripheral and central adenosine A1 receptors. ( Cidral-Filho, FJ; Martins, DF; Mazzardo-Martins, L; Santos, AR; Stramosk, J, 2013) |
| "Neuropathic pain is often "spontaneous" or "stimulus-independent." | 1.37 | Lesion of the rostral anterior cingulate cortex eliminates the aversiveness of spontaneous neuropathic pain following partial or complete axotomy. ( Fields, HL; King, T; Lai, J; Okun, A; Porreca, F; Qu, C, 2011) |
| "PSNL induced bilateral behavioral hyperalgesia, with the ipsilateral level displaying a higher extent of behavior changes than the contralateral side." | 1.37 | Effects of clonidine on bilateral pain behaviors and inflammatory response in rats under the state of neuropathic pain. ( Dong, R; Feng, X; Li, W; Liu, J; Wang, H; Xu, J; Yu, B; Zhang, F, 2011) |
| "Thermal hyperalgesia provoked by phenylephrine was inhibited by terazosin administered after the burn injury, but not by terazosin administered before the burn injury." | 1.35 | alpha(1)-Adrenoceptors augment thermal hyperalgesia in mildly burnt skin. ( Drummond, PD, 2009) |
| " In the mouse formalin test, DBV injection produced a dramatic leftward shift in the dose-response curve for clonidine-induced analgesia." | 1.35 | Acupoint stimulation with diluted bee venom (apipuncture) potentiates the analgesic effect of intrathecal clonidine in the rodent formalin test and in a neuropathic pain model. ( Beitz, AJ; Han, HJ; Kim, HW; Kwon, YB; Lee, HJ; Lee, JH; Roh, DH; Seo, HS; Yoon, SY, 2009) |
| "In contrast, during hyperalgesia, alpha(2)-adrenergic activation enhances TNFalpha mRNA accumulation." | 1.34 | Antinociception mediated by alpha(2)-adrenergic activation involves increasing tumor necrosis factor alpha (TNFalpha) expression and restoring TNFalpha and alpha(2)-adrenergic inhibition of norepinephrine release. ( Ignatowski, TA; Knight, PR; Spengler, RN; Sud, R, 2007) |
| "Clonidine was used as a reference alpha 2 -adrenoceptor agonist." | 1.32 | Comparison of the visceral antinociceptive effects of spinally administered MPV-2426 (fadolmidine) and clonidine in the rat. ( Kalmari, J; Pertovaara, A, 2003) |
| " In combination with either low or high frequency TENS, the dose-response curve shifted to the left and was significantly different from clonidine alone." | 1.31 | Enhanced reduction in hyperalgesia by combined administration of clonidine and TENS. ( Chandran, P; Sluka, KA, 2002) |
| " Furthermore, the combinations of moxonidine-morphine and clonidine-morphine resulted in substantial leftward shifts in the dose-response curves compared with those of each agonist administered separately." | 1.31 | Moxonidine, a selective imidazoline-alpha2 -adrenergic receptor agonist, produces spinal synergistic antihyperalgesia with morphine in nerve-injured mice. ( Fairbanks, CA; Grocholski, BM; Nguyen, HO; Wilcox, GL, 2000) |
| "Tizanidine was effective in reducing sensitivity to heat, as measured by paw withdrawal latency, and did not cause sedation at smaller doses." | 1.31 | Systemic tizanidine hydrochloride (Zanaflex) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. ( Azevedo, MI; Chalfoun, AG; Denson, DD; Hord, AH, 2001) |
| " We used the tail-flick test to construct dose-response curves before and 4 days after chronic morphine (75-mg pellets, subcutaneously (s." | 1.31 | Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKC gamma mutant mice. ( Basbaum, AI; Gilbert, H; Malmberg, AB; Zeitz, KP, 2001) |
| "CFA injection resulted in significant thermal hyperalgesia throughout the four days of observation." | 1.31 | Intrathecal clonidine decreases spinal nitric oxide release in a rat model of complete Freund's adjuvant induced inflammatory pain. ( Cheng, JT; Chuang, YC; Lin, CR; Wang, CJ; Yang, LC, 2002) |
| "Morphine pre-treatment was less effective in preventing development of hyperalgesia; however, whilst the ipsilateral (146 +/- 18 g) paw withdrawal threshold tended to be lower than the contralateral (183 +/- 8 g), this was not significant." | 1.29 | Pre-emptive administration of clonidine prevents development of hyperalgesia to mechanical stimuli in a model of mononeuropathy in the rat. ( Birch, PJ; Elliott, PJ; Harrison, SM; Smith, GD; Wiseman, J, 1993) |
| "Evidence suggests that the pain and hyperalgesia in SMP are related to activation of peripheral adrenergic receptors." | 1.28 | Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. ( Campbell, JN; Davis, KD; Meyer, RA; Raja, SN; Treede, RD, 1991) |
| " Dose-response curves for intrathecally administered agonists with mu- and/or delta-opioid activity were shifted to the left for inflamed hindpaws when compared to contralateral non-inflamed paws." | 1.28 | Spinal opioid analgesic effects are enhanced in a model of unilateral inflammation/hyperalgesia: possible involvement of noradrenergic mechanisms. ( Dubner, R; Hylden, JL; Iadarola, MJ; Nahin, RL; Thomas, DA, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (8.82) | 18.2507 |
| 2000's | 34 (50.00) | 29.6817 |
| 2010's | 25 (36.76) | 24.3611 |
| 2020's | 3 (4.41) | 2.80 |
| Authors | Studies |
|---|---|
| Rodríguez-Palma, EJ | 1 |
| Castelo-Flores, DG | 1 |
| Caram-Salas, NL | 1 |
| Salinas-Abarca, AB | 1 |
| Centurión, D | 1 |
| De la Luz-Cuellar, YE | 1 |
| Granados-Soto, V | 1 |
| Huang, H | 1 |
| Bai, X | 2 |
| Zhang, K | 1 |
| Guo, J | 1 |
| Wu, S | 1 |
| Ouyang, H | 2 |
| Yoon, SY | 3 |
| Roh, DH | 3 |
| Yeo, JH | 2 |
| Woo, J | 1 |
| Han, SH | 1 |
| Kim, KS | 1 |
| Naja, Z | 1 |
| Naja, AS | 1 |
| Ankouni, T | 1 |
| Mugharbil, A | 1 |
| Drummond, PD | 2 |
| Morellini, N | 1 |
| Finch, PM | 1 |
| Birklein, F | 1 |
| Knudsen, LF | 1 |
| Zhu, JX | 1 |
| Xu, FY | 1 |
| Xu, WJ | 1 |
| Zhao, Y | 1 |
| Qu, CL | 1 |
| Tang, JS | 1 |
| Barry, DM | 1 |
| Du, JQ | 1 |
| Huo, FQ | 1 |
| Ohnesorge, H | 1 |
| Feng, Z | 1 |
| Zitta, K | 1 |
| Steinfath, M | 1 |
| Albrecht, M | 1 |
| Bein, B | 1 |
| Park, PE | 1 |
| Schlosburg, JE | 1 |
| Vendruscolo, LF | 1 |
| Schulteis, G | 1 |
| Edwards, S | 1 |
| Koob, GF | 1 |
| Laferrière, A | 2 |
| Abaji, R | 1 |
| Tsai, CY | 1 |
| Ragavendran, JV | 2 |
| Coderre, TJ | 2 |
| Rauck, RL | 1 |
| North, J | 1 |
| Eisenach, JC | 8 |
| Lee, MG | 1 |
| Lee, DK | 1 |
| Huh, BK | 1 |
| Choi, SS | 1 |
| Kim, HZ | 1 |
| Lim, BG | 1 |
| Kim, HS | 1 |
| Choi, YS | 1 |
| Hur, WS | 1 |
| Lee, MK | 1 |
| Zuo, ZX | 1 |
| Wang, YJ | 1 |
| Liu, L | 1 |
| Wang, Y | 1 |
| Mei, SH | 1 |
| Feng, ZH | 1 |
| Wang, M | 1 |
| Li, XY | 1 |
| Kim, SJ | 1 |
| Oh, SB | 1 |
| Lee, JH | 2 |
| Beitz, AJ | 2 |
| Bennett, GJ | 1 |
| Ware, MA | 1 |
| Gandhi, W | 1 |
| Bley, K | 1 |
| Schweinhardt, P | 1 |
| Nag, S | 1 |
| Mokha, SS | 1 |
| Zhang, L | 1 |
| Wang, G | 1 |
| Ma, J | 1 |
| Liu, C | 1 |
| Liu, X | 1 |
| Zhan, Y | 1 |
| Zhang, M | 1 |
| Kwon, YB | 1 |
| Kim, HW | 1 |
| Seo, HS | 1 |
| Han, HJ | 1 |
| Lee, HJ | 2 |
| Gil, DW | 2 |
| Cheevers, CV | 2 |
| Kedzie, KM | 1 |
| Manlapaz, CA | 1 |
| Rao, S | 1 |
| Tang, E | 1 |
| Donello, JE | 2 |
| Feng, X | 2 |
| Zhang, F | 2 |
| Dong, R | 2 |
| Li, W | 2 |
| Liu, J | 2 |
| Zhao, X | 1 |
| Xue, Q | 1 |
| Yu, B | 2 |
| Xu, J | 2 |
| Gyires, K | 1 |
| Zádori, ZS | 1 |
| Shujaa, N | 1 |
| Al-Khrasani, M | 1 |
| Pap, B | 1 |
| Mózes, MM | 1 |
| Mátyus, P | 1 |
| King, T | 2 |
| Vera-Portocarrero, L | 1 |
| Gutierrez, T | 1 |
| Vanderah, TW | 1 |
| Dussor, G | 1 |
| Lai, J | 2 |
| Fields, HL | 2 |
| Porreca, F | 2 |
| Overland, AC | 1 |
| Kitto, KF | 1 |
| Chabot-Doré, AJ | 1 |
| Rothwell, PE | 1 |
| Fairbanks, CA | 2 |
| Stone, LS | 1 |
| Wilcox, GL | 2 |
| Chen, JJ | 1 |
| Lue, JH | 1 |
| Lin, LH | 1 |
| Huang, CT | 1 |
| Chiang, RP | 1 |
| Chen, CL | 1 |
| Tsai, YJ | 1 |
| Qu, C | 1 |
| Okun, A | 1 |
| Davoody, L | 1 |
| Quiton, RL | 1 |
| Lucas, JM | 1 |
| Ji, Y | 1 |
| Keller, A | 1 |
| Masri, R | 1 |
| Schlimp, CJ | 1 |
| Pipam, W | 1 |
| Wolrab, C | 1 |
| Ohner, C | 1 |
| Kager, HI | 1 |
| Likar, R | 1 |
| Kim, HJ | 1 |
| Seol, TK | 1 |
| Yaksh, TL | 2 |
| Jun, JH | 1 |
| Wang, H | 1 |
| Huang, W | 1 |
| Chen, D | 1 |
| Dohi, S | 2 |
| Zeng, W | 2 |
| Walker, SM | 1 |
| Grafe, M | 1 |
| Blaudszun, G | 1 |
| Lysakowski, C | 1 |
| Elia, N | 1 |
| Tramèr, MR | 1 |
| Martins, DF | 1 |
| Mazzardo-Martins, L | 1 |
| Cidral-Filho, FJ | 1 |
| Stramosk, J | 1 |
| Santos, AR | 1 |
| Wei, H | 1 |
| Viisanen, H | 1 |
| Amorim, D | 1 |
| Koivisto, A | 1 |
| Pertovaara, A | 3 |
| Milne, B | 1 |
| Jhamandas, K | 1 |
| Sutak, M | 1 |
| Grenier, P | 1 |
| Cahill, CM | 1 |
| Lin, CR | 1 |
| Chuang, YC | 1 |
| Cheng, JT | 1 |
| Wang, CJ | 1 |
| Yang, LC | 1 |
| Sluka, KA | 1 |
| Chandran, P | 1 |
| Kalmari, J | 1 |
| Jevtovic-Todorovic, V | 1 |
| Meyenburg, AP | 1 |
| Olney, JW | 1 |
| Wozniak, DF | 1 |
| Kawamata, T | 1 |
| Omote, K | 1 |
| Yamamoto, H | 1 |
| Toriyabe, M | 1 |
| Wada, K | 1 |
| Namiki, A | 1 |
| Koppert, W | 1 |
| Sittl, R | 1 |
| Scheuber, K | 1 |
| Alsheimer, M | 1 |
| Schmelz, M | 1 |
| Schüttler, J | 1 |
| Lavand'homme, PM | 1 |
| Obata, H | 1 |
| Li, X | 1 |
| Miura, T | 1 |
| Okazaki, R | 1 |
| Yoshida, H | 1 |
| Namba, H | 1 |
| Okai, H | 1 |
| Kawamura, M | 1 |
| De Kock, M | 1 |
| Lavand'homme, P | 1 |
| Waterloos, H | 1 |
| Romero-Sandoval, EA | 1 |
| McCall, C | 1 |
| Liu, B | 1 |
| Martin, TJ | 1 |
| Kim, SA | 1 |
| Dogrul, A | 1 |
| Coskun, I | 1 |
| Uzbay, T | 1 |
| Ge, YX | 1 |
| Xin, WJ | 1 |
| Hu, NW | 1 |
| Zhang, T | 1 |
| Xu, JT | 1 |
| Liu, XG | 1 |
| Spengler, RN | 2 |
| Sud, R | 1 |
| Knight, PR | 2 |
| Ignatowski, TA | 2 |
| Reuben, SS | 1 |
| Buvanendran, A | 1 |
| Chen, X | 1 |
| Tomić, MA | 1 |
| Vucković, SM | 1 |
| Stepanović-Petrović, RM | 1 |
| Ugresić, ND | 1 |
| Paranos, SLj | 1 |
| Prostran, MS | 1 |
| Bosković, B | 1 |
| Smith, GD | 2 |
| Harrison, SM | 2 |
| Birch, PJ | 2 |
| Wiseman, J | 1 |
| Elliott, PJ | 1 |
| Aley, KO | 1 |
| Levine, JD | 1 |
| Hood, DD | 2 |
| Curry, R | 2 |
| Wang, YX | 1 |
| Pettus, M | 1 |
| Gao, D | 1 |
| Phillips, C | 1 |
| Scott Bowersox, S | 1 |
| Covey, WC | 1 |
| Onttonen, T | 1 |
| Nguyen, HO | 1 |
| Grocholski, BM | 1 |
| Hord, AH | 1 |
| Chalfoun, AG | 1 |
| Denson, DD | 1 |
| Azevedo, MI | 1 |
| Zeitz, KP | 1 |
| Malmberg, AB | 1 |
| Gilbert, H | 1 |
| Basbaum, AI | 1 |
| Davis, KD | 1 |
| Treede, RD | 1 |
| Raja, SN | 1 |
| Meyer, RA | 1 |
| Campbell, JN | 1 |
| Hylden, JL | 1 |
| Thomas, DA | 1 |
| Iadarola, MJ | 1 |
| Nahin, RL | 1 |
| Dubner, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Topical Treatment With Clonidine + Pentoxifylline in Patients With Neuropathic Pain[NCT03342950] | Phase 2 | 4 participants (Actual) | Interventional | 2019-02-19 | Terminated (stopped due to Low recruitment due to the COVID-19 pandemic) | ||
| A Prospective Study Comparing Total Intravenous Anesthesia With Propofol and Remifentanil vs. Propofol and Dexmedetomidine in Adolescent Idiopathic Scoliosis Patients Undergoing Posterior Spinal Fusion and Instrumentation[NCT06096181] | Phase 2 | 120 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Intravenous Lidocaine and Time to Regression of the Sensory Block After Spinal Anesthesia With Isobaric Bupivacaine in Patients Undergoing Surgery to Treat Skin and Soft Tissue Tumors of the Lower Limbs[NCT04741880] | Phase 2/Phase 3 | 66 participants (Anticipated) | Interventional | 2021-06-17 | Recruiting | ||
| Guanfacine for PONV and Pain After Sinus Surgery[NCT02882854] | 84 participants (Actual) | Interventional | 2016-11-30 | Completed | |||
| A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain[NCT02289261] | Phase 4 | 40 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease, a Pilot Study[NCT02801292] | Phase 3 | 20 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia Using Filaments, an Algometer, and Interleukins: a Double-blind, Randomized Study[NCT01301079] | Phase 3 | 60 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia[NCT03066739] | Phase 2 | 105 participants (Anticipated) | Interventional | 2023-02-25 | Recruiting | ||
| Can Opioid-induced Hyperalgesia be Prevented by Gradual Dose Reduction vs. Abrupt Withdrawal of Remifentanil?[NCT01702389] | Phase 4 | 16 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Hemodynamic Effect of Intrathecal Clonidine in Hypertensive Subjects: A Pilot Study to Assess Its Effectiveness in Hypertensive Subjects With Poor Blood Pressure Control (Phase II)[NCT01297335] | Phase 2 | 10 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Effects of Lidocaine Patch on Intradermal Capsaicin Induced Pain and Hyperalgesia[NCT00373893] | Phase 1 | 12 participants | Interventional | 2005-12-31 | Completed | ||
| Clinical Trial of Etanercept (TNF-α Blocker) for Treatment of Blast-Induced Tinnitus[NCT04066348] | Phase 2 | 310 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02882854)
Timeframe: Time frame between arrival and discharge in PACU, approximately 90 minutes
| Intervention | minutes (Median) |
|---|---|
| Guanfacine | 128 |
| Placebo | 110 |
PONV assessed using nVRS at 24 hours postop when 0 is no nausea and 10 is worst nausea. (NCT02882854)
Timeframe: 24 hours post op
| Intervention | score on a scale (Median) |
|---|---|
| Guanfacine | 0.00 |
| Placebo | 0.00 |
Postoperative pain assessment using VAS at 24 hours postop when 0 is no pain and 10 is worst pain (NCT02882854)
Timeframe: 24 hours postop
| Intervention | score on a scale (Median) |
|---|---|
| Guanfacine | 3 |
| Placebo | 2 |
Total narcotic requirement in PACU tallied in morphine equivalents during PACU stay (NCT02882854)
Timeframe: Time frame between arrival and discharge in PACU, approximately 90 minutes
| Intervention | morphine equivalents (Median) |
|---|---|
| Guanfacine | 8.75 |
| Placebo | 7.50 |
Maximum postoperative pain assessment assessed in PACU at 15, 30 and 60 minutes after PACU arrival using VAS when 0 is no pain and 10 is worst pain (NCT02882854)
Timeframe: 15, 30, 60 minutes after arriving in PACU
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 minutes after PACU admission72482977 | 15 minutes after PACU admission72482978 | 30 minutes after PACU admission72482977 | 30 minutes after PACU admission72482978 | 60 minutes after PACU admission72482977 | 60 minutes after PACU admission72482978 | |||||||||||||
| Mild (Pain nVRS 1-5) | Moderate/Severe (Pain nVRS 6-10) | None (Pain nVRS 0) | ||||||||||||||||
| Guanfacine | 31 | |||||||||||||||||
| Placebo | 24 | |||||||||||||||||
| Guanfacine | 0 | |||||||||||||||||
| Placebo | 5 | |||||||||||||||||
| Guanfacine | 8 | |||||||||||||||||
| Placebo | 10 | |||||||||||||||||
| Guanfacine | 18 | |||||||||||||||||
| Placebo | 20 | |||||||||||||||||
| Guanfacine | 7 | |||||||||||||||||
| Placebo | 6 | |||||||||||||||||
| Guanfacine | 14 | |||||||||||||||||
| Placebo | 14 | |||||||||||||||||
| Guanfacine | 12 | |||||||||||||||||
| Placebo | 16 | |||||||||||||||||
| Guanfacine | 6 | |||||||||||||||||
| Placebo | 13 | |||||||||||||||||
| Guanfacine | 21 | |||||||||||||||||
| Placebo | 12 | |||||||||||||||||
The evaluations using the soft brush were performed 2-3 cm from the incision in the periumbilical region (where the large trocar was placed) 24 h after the procedure (NCT01301079)
Timeframe: 24 h after the procedure
| Intervention | participants (Number) |
|---|---|
| Ketamine | 1 |
| Saline | 0 |
The evaluations using the soft brush were performed 2-3 cm from the incision in the periumbilical region (where the large trocar was placed) before the procedure (NCT01301079)
Timeframe: Before the procedure (Baseline)
| Intervention | participants (Number) |
|---|---|
| Ketamine | 1 |
| Saline | 0 |
The evaluations using the soft brush were performed in the thenar eminence of the non dominant hand 24 h after the procedure (NCT01301079)
Timeframe: 24 h after the procedure
| Intervention | participants (Number) |
|---|---|
| Ketamine | 1 |
| Saline | 3 |
The evaluations using the soft brush were performed in the thenar eminence of the nondominant hand before the procedure (NCT01301079)
Timeframe: Before the procedure (Baseline)
| Intervention | participants (Number) |
|---|---|
| Ketamine | 1 |
| Saline | 0 |
The 300-g filament was used 24 hours after the operation to induce a stimulus and delineate the extent of hyperalgesia from the periumbilical region. The stimulus was started outside the periumbilical region, where no pain sensation was reported, and continued every 0.5 cm until the 4 points of the periumbilical scar were reached (top, right side, left side, and bottom). The first point where the patient complained of pain was marked. If no pain sensation was reported, the stimulus was terminated 0.5 cm from the incision. The distance of each point from the surgical incision was measured, and the sum of the distances of the points was determined. (NCT01301079)
Timeframe: 24 hours after the procedure
| Intervention | centimeter (Mean) |
|---|---|
| Ketamine | 10.61 |
| Saline | 11.82 |
The mechanical pain threshold was evaluated using an algometer. The pressure was increased by 0.1 kgf/second until the patient complained of pain. The mean of three determinations was calculated. (NCT01301079)
Timeframe: 24 h after the procedure
| Intervention | kilogram force/second (Mean) |
|---|---|
| Ketamine | 3.5 |
| Saline | 3.7 |
The mechanical pain threshold was evaluated using an algometer. The pressure was increased by 0.1 kgf/second until the patient complained of pain. The mean of three determinations was calculated. (NCT01301079)
Timeframe: 24 h after the procedure
| Intervention | kilogram force/second (Mean) |
|---|---|
| Ketamine | 0.56 |
| Saline | 0.51 |
The pain threshold was assessed using six von Frey monofilaments (0,05 g; 0,2 g; 2 g; 4 g; 10 g e 300 g) in the periumbilical region in the postoperative period (24h after the procedure). The use of different von Frey monofilaments, starting with the lightest and ending with the heaviest, was separated by at least 30 seconds to reduce any anticipated responses due to a new stimulation that was performed too soon after the preceding stimulation. Three assessments were made for each monofilament, and this was considered positive when the patient responded to two of the determinations for each monofilament. (NCT01301079)
Timeframe: 24h after the procedure
| Intervention | gram (Mean) |
|---|---|
| Ketamine | 248 |
| Saline | 205 |
The pain threshold was assessed using six von Frey monofilaments (0,05 g; 0,2 g; 2 g; 4 g; 10 g e 300 g) in thenar eminence in the postoperative period (24 hours after procedure). The use of different von Frey monofilaments, starting with the lightest and ending with the heaviest, was separated by at least 30 seconds to reduce any anticipated responses due to a new stimulation that was performed too soon after the preceding stimulation. Three assessments were made for each monofilament, and this was considered positive when the patient responded to two of the determinations for each monofilament. (NCT01301079)
Timeframe: 24 hours after procedure
| Intervention | gram (Mean) |
|---|---|
| Ketamine | 290 |
| Saline | 247 |
The mechanical pain threshold was evaluated using an algometer. The pressure was increased by 0.1 kgf/second until the patient complained of pain. The mean of three determinations was calculated. (NCT01301079)
Timeframe: Baseline (before the surgery)
| Intervention | kilogram force/second (Mean) |
|---|---|
| Ketamine | 3.6 |
| Saline | 3.9 |
The mechanical pain threshold was evaluated using an algometer. The pressure was increased by 0.1 kgf/second until the patient complained of pain. The mean of three determinations was calculated. (NCT01301079)
Timeframe: Baseline (before the procedure)
| Intervention | kilogram force/second (Mean) |
|---|---|
| Ketamine | 2.51 |
| Saline | 2.19 |
The pain threshold was assessed using six von Frey monofilaments (0,05 g; 0,2 g; 2 g; 4 g; 10 g e 300 g) in the periumbilical region in the preoperative period. The use of different von Frey monofilaments, starting with the lightest and ending with the heaviest, was separated by at least 30 seconds to reduce any anticipated responses due to a new stimulation that was performed too soon after the preceding stimulation. Three assessments were made for each monofilament, and this was considered positive when the patient responded to two of the determinations for each monofilament. (NCT01301079)
Timeframe: Before the procedure (Baseline)
| Intervention | gram (Mean) |
|---|---|
| Ketamine | 279 |
| Saline | 269 |
The pain threshold was assessed using six von Frey monofilaments (0,05 g; 0,2 g; 2 g; 4 g; 10 g e 300 g) in thenar eminence in the preoperative period. The use of different von Frey monofilaments, starting with the lightest and ending with the heaviest, was separated by at least 30 seconds to reduce any anticipated responses due to a new stimulation that was performed too soon after the preceding stimulation. Three assessments were made for each monofilament, and this was considered positive when the patient responded to two of the determinations for each monofilament. (NCT01301079)
Timeframe: Before the procedure (Baseline)
| Intervention | gram (Mean) |
|---|---|
| Ketamine | 300 |
| Saline | 300 |
(NCT01301079)
Timeframe: 24 hours
| Intervention | milligram (Mean) |
|---|---|
| Ketamine | 27.40 |
| Saline | 27.70 |
The scale measure pain after 12 hours (0 - without pain and 10 worst pain possible). The individual can choose any number between 0 - 10. (NCT01301079)
Timeframe: 12 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 1.6 |
| Saline | 1.4 |
The scale measure pain after 120 minutes (0 - without pain and 10 worst pain possible). The individual can choose any number between 0 - 10. (NCT01301079)
Timeframe: 120 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 2.2 |
| Saline | 2.0 |
The scale measure pain after 150 minutes (0 - without pain and 10 worst pain possible). The individual can choose any number between 0 - 10. (NCT01301079)
Timeframe: 150 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 1.4 |
| Saline | 1.4 |
The scale measure pain after 18 hours (0 - without pain and 10 worst pain possible). The individual can choose any number between 0 - 10. (NCT01301079)
Timeframe: 18 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 1.5 |
| Saline | 1.3 |
The scale measure pain after 180 minutes (0 - without pain and 10 worst pain possible). The individual can choose any number between 0 - 10. (NCT01301079)
Timeframe: 180 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 1.1 |
| Saline | 1.3 |
The scale measure pain after 210 minutes (0 - without pain and 10 worst pain possible). The individual can choose any number between 0 - 10. (NCT01301079)
Timeframe: 210 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 0.9 |
| Saline | 1.2 |
The scale measure pain after 24 hours (0 - without pain and 10 worst pain possible). The individual can choose any number between 0 - 10. (NCT01301079)
Timeframe: 24 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 1.4 |
| Saline | 0.8 |
The scale measure pain after 240 minutes (0 - without pain and 10 worst pain possible). The individual can choose any number between 0 - 10. (NCT01301079)
Timeframe: 240 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 1.0 |
| Saline | 1.1 |
The scale measure pain after 30 minutes (0 - without pain and 10 worst pain possible). The individual can choose any number between 0 - 10. (NCT01301079)
Timeframe: 30 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 5.5 |
| Saline | 6.2 |
The scale measure pain after 6 hours (0 - without pain and 10 worst pain possible). The individual can choose any number between 0 - 10. (NCT01301079)
Timeframe: 6 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 0.9 |
| Saline | 0.7 |
The scale measure pain after 60 minutes (0 - without pain and 10 worst pain possible). The individual can choose any number between 0 - 10. (NCT01301079)
Timeframe: 60 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 4.6 |
| Saline | 5.1 |
The scale measure pain after 90 minutes (0 - without pain and 10 worst pain possible). The individual can choose any number between 0 - 10. (NCT01301079)
Timeframe: 90 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 3.4 |
| Saline | 3.4 |
Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes 24 h after the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-6 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology. (NCT01301079)
Timeframe: 24 h after the procedure
| Intervention | picogram/milliliter (Mean) |
|---|---|
| Ketamine | 8.6 |
| Saline | 5.0 |
Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes 5 h after the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-10 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology. (NCT01301079)
Timeframe: 5h after the procedure
| Intervention | picogram/milliliter (Mean) |
|---|---|
| Ketamine | 9.1 |
| Saline | 5.5 |
Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes before the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-6 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology. (NCT01301079)
Timeframe: Baseline (Before the procedure)
| Intervention | picogram/milliliter (Mean) |
|---|---|
| Ketamine | 7.8 |
| Saline | 1.9 |
Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes 24 h after the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-6 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology. (NCT01301079)
Timeframe: 24 h after the procedure
| Intervention | picogram/milliliter (Mean) |
|---|---|
| Ketamine | 24.1 |
| Saline | 24.8 |
Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes 5 h after the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-6 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology. (NCT01301079)
Timeframe: 5 h after the procedure
| Intervention | picogram/milliliter (Mean) |
|---|---|
| Ketamine | 29.3 |
| Saline | 34.8 |
Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes before the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-6 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology. (NCT01301079)
Timeframe: Baseline (Before the procedure)
| Intervention | picogram/milliliter (Mean) |
|---|---|
| Ketamine | 3.3 |
| Saline | 2.1 |
Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes 24 h after the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-8 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology. (NCT01301079)
Timeframe: 24 h after the procedure
| Intervention | picogram/milliliter (Mean) |
|---|---|
| Ketamine | 6.0 |
| Saline | 4.5 |
Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes 5 h after the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-8 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology. (NCT01301079)
Timeframe: 5 h after the procedure
| Intervention | picogram/milliliter (Mean) |
|---|---|
| Ketamine | 8.0 |
| Saline | 11.3 |
Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes before the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-8 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology. (NCT01301079)
Timeframe: Baseline (Before the procedure)
| Intervention | picogram/milliliter (Mean) |
|---|---|
| Ketamine | 3.3 |
| Saline | 2.2 |
(NCT01301079)
Timeframe: 24 hours
| Intervention | minutes (Median) |
|---|---|
| Ketamine | 18 |
| Saline | 15 |
"Subjects baseline blood pressure (systolic blood pressure (SBP), and diastolic blood pressure (DBP)), and blood pressures after clonidine injection was compared against baseline to assess efficacy of clonidine in refractory hypertensive subjects. Subject's blood pressure was monitored continuously after intrathecal injection of clonidine until subjects blood pressure nadir and return to pre clonidine injection level. The mean value reported below are the average changes in blood pressure from baseline (pre clonidine injection) in both SBP and DBP during post clonidine injection blood pressure monitoring for 4 hours.~Blood pressure measurements were collected every 10 minutes for first hour after injection, and every 15 minutes after the first hour, up to 4 hours were averaged to report the change from baseline." (NCT01297335)
Timeframe: Baseline, Every 10 Minutes for first hour after clonidine injection, and every 15 minutes after first hour, until 4 hours after clonidine injection
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in mean SBP after clonidine injection | Change in DBP after clonidine injection | |
| Intrathecal Clonidine | 79 | 37 |
Subjects were asked to rate severity of two of the most common side effects of clonidine, sedation and sensation of dry mouth, at pre and post (1 hour after) intrathecal administration of clonidine. The mean changes between pre and post injection VAS ratings of sedation and sensation of dry mouth are reported below. The VAS scale ranges from 1 to 10 cm, with higher values indicating higher level of sedation and higher level of dry mouth. (NCT01297335)
Timeframe: Before clonidine injection (Baseline), and at 1 hour after clonidine injection.
| Intervention | cm (Mean) | |
|---|---|---|
| Change in level of sedation | Change in sensation of dry mouth | |
| Intrathecal Clonidine | 3.36 | 3.47 |
Likert scale is 11 point digital pain rating system that asks subjects to rate their pain from 0 to 10. Rating of 0 means no pain at all, and in increasing order, 10 would mean worst pain imaginable/ unbearable pain. (NCT01297335)
Timeframe: Pre-dose and 1 hour post injection.
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Pre-injection average Likert score | Post-injection average Likert score | |
| Intrathecal Clonidine | 6.5 | 3.6 |
2 reviews available for clonidine and Allodynia
7 trials available for clonidine and Allodynia
| Article | Year |
|---|---|
Intrathecal clonidine and adenosine: effects on pain and sensory processing in patients with chronic regional pain syndrome.
Topics: Adenosine; Adult; Analgesics; Chronic Pain; Clonidine; Complex Regional Pain Syndromes; Cross-Over S | 2015 |
Effects of topical combinations of clonidine and pentoxifylline on capsaicin-induced allodynia and postcapsaicin tourniquet-induced pain in healthy volunteers: a double-blind, randomized, controlled study.
Topics: Adolescent; Adult; Analgesics; Capsaicin; Clonidine; Double-Blind Method; Drug Therapy, Combination; | 2016 |
[Clonidine for remifentanil-induced hyperalgesia: a double-blind randomized, placebo-controlled study of clonidine under intra-operative use of remifentanil in elective surgery of the shoulder].
Topics: Adult; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthetics, Intravenous; Arth | 2011 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Anesthetics, Dissociative; Blood Pressure; Clo | 2003 |
The short-lasting analgesia and long-term antihyperalgesic effect of intrathecal clonidine in patients undergoing colonic surgery.
Topics: Adrenergic alpha-Agonists; Aged; Analgesia; Analgesia, Patient-Controlled; Analgesics, Opioid; Anest | 2005 |
Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics; Blood Pressure; Capsaicin; Clonidine; Double-Blind Met | 1998 |
Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics; Blood Pressure; Capsaicin; Clonidine; Double-Blind Met | 1998 |
Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics; Blood Pressure; Capsaicin; Clonidine; Double-Blind Met | 1998 |
Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers.
Topics: Adrenergic alpha-Agonists; Adult; Analgesics; Blood Pressure; Capsaicin; Clonidine; Double-Blind Met | 1998 |
Relative potency of epidural to intrathecal clonidine differs between acute thermal pain and capsaicin-induced allodynia.
Topics: Adult; Analgesics; Blood Pressure; Capsaicin; Clonidine; Dose-Response Relationship, Drug; Female; H | 2000 |
59 other studies available for clonidine and Allodynia
| Article | Year |
|---|---|
Sex-dependent antiallodynic effect of α
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Clonidine; Female; Hyperalgesia; Male; Neuralgia; Rat | 2022 |
Antinociceptive Effects and Interaction Mechanisms of Intrathecal Pentazocine and Neostigmine in Two Different Pain Models in Rats.
Topics: Analgesics; Animals; Atropine Derivatives; Clonidine; Formaldehyde; Humans; Hyperalgesia; Naloxone; | 2022 |
Analgesic Efficacy of α
Topics: Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Analgesics; An | 2021 |
Thoracic paravertebral catheterization for more than one year: A report of mastodynia.
Topics: Analgesics; Anesthetics, Local; Catheterization; Clonidine; Electric Injuries; Epidural Space; Femal | 2018 |
Complex regional pain syndrome: intradermal injection of phenylephrine evokes pain and hyperalgesia in a subgroup of patients with upregulated α1-adrenoceptors on dermal nerves.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Clonidine; | 2018 |
The role of α₂ adrenoceptor in mediating noradrenaline action in the ventrolateral orbital cortex on allodynia following spared nerve injury.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Bicuculline; | 2013 |
Influence of clonidine and ketamine on m-RNA expression in a model of opioid-induced hyperalgesia in mice.
Topics: Analgesics, Opioid; Animals; Arrestins; beta-Arrestin 2; beta-Arrestins; Brain; Clonidine; Disease M | 2013 |
Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antag | 2015 |
Topical combinations to treat microvascular dysfunction of chronic postischemia pain.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Animals; Capillaries; Chemistry, Phar | 2014 |
The effect of clonidine pretreatment on epidural resiniferatoxin in a neuropathic pain rat model.
Topics: Analgesia, Epidural; Analgesics; Animals; Clonidine; Diterpenes; Hyperalgesia; Injections, Epidural; | 2015 |
Huperzine A Alleviates Mechanical Allodynia but Not Spontaneous Pain via Muscarinic Acetylcholine Receptors in Mice.
Topics: Acetylcholinesterase; Alkaloids; Ambenonium Chloride; Analgesics; Animals; Atropine; Behavior, Anima | 2015 |
Clonidine, an alpha-2 adrenoceptor agonist relieves mechanical allodynia in oxaliplatin-induced neuropathic mice; potentiation by spinal p38 MAPK inhibition without motor dysfunction and hypotension.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antineoplastic Agents; Blood Pressure; Clonidine; Cyt | 2016 |
Activation of the trigeminal α2-adrenoceptor produces sex-specific, estrogen dependent thermal antinociception and antihyperalgesia using an operant pain assay in the rat.
Topics: Analgesics; Animals; Clonidine; Estrogens; Female; Hyperalgesia; Male; Ovariectomy; Pain; Pain Measu | 2016 |
Brain-derived neurotrophic factor (BDNF) in the rostral anterior cingulate cortex (rACC) contributes to neuropathic spontaneous pain-related aversion via NR2B receptors.
Topics: Analgesics; Animals; Avoidance Learning; Brain-Derived Neurotrophic Factor; Clonidine; Conditioning, | 2016 |
alpha(1)-Adrenoceptors augment thermal hyperalgesia in mildly burnt skin.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adult; Burns; Clonidine; Female | 2009 |
Acupoint stimulation with diluted bee venom (apipuncture) potentiates the analgesic effect of intrathecal clonidine in the rodent formalin test and in a neuropathic pain model.
Topics: Acupuncture Points; Analgesics; Animals; Bee Venoms; Clonidine; Disease Models, Animal; Dose-Respons | 2009 |
Alpha-1-adrenergic receptor agonist activity of clinical alpha-adrenergic receptor agonists interferes with alpha-2-mediated analgesia.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Analg | 2009 |
Intrathecal administration of clonidine attenuates spinal neuroimmune activation in a rat model of neuropathic pain with existing hyperalgesia.
Topics: Animals; Behavior, Animal; Biomarkers; Clonidine; Cytokines; Disease Models, Animal; Enzyme Activati | 2009 |
Pharmacological analysis of alpha(2)-adrenoceptor subtypes mediating analgesic, anti-inflammatory and gastroprotective actions.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agon | 2009 |
Unmasking the tonic-aversive state in neuropathic pain.
Topics: Adenosine; Analgesics; Analysis of Variance; Animals; Calcium Channel Blockers; Clonidine; Condition | 2009 |
Protein kinase C mediates the synergistic interaction between agonists acting at alpha2-adrenergic and delta-opioid receptors in spinal cord.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Anesthetics, Local; Animals; Calcit | 2009 |
Effects of pre-emptive drug treatment on astrocyte activation in the cuneate nucleus following rat median nerve injury.
Topics: Adrenergic alpha-Agonists; Animals; Astrocytes; Citrates; Clonidine; Disease Models, Animal; Dizocil | 2010 |
Lesion of the rostral anterior cingulate cortex eliminates the aversiveness of spontaneous neuropathic pain following partial or complete axotomy.
Topics: Analgesics; Animals; Avoidance Learning; Axotomy; Clonidine; Cocaine; Conditioning, Operant; Disease | 2011 |
Conditioned place preference reveals tonic pain in an animal model of central pain.
Topics: Analgesics; Animals; Buprenorphine; Clonidine; Conditioning, Operant; Disease Models, Animal; Electr | 2011 |
The effect of intrathecal mu, delta, kappa, and alpha-2 agonists on thermal hyperalgesia induced by mild burn on hind paw in rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic | 2011 |
Effects of clonidine on bilateral pain behaviors and inflammatory response in rats under the state of neuropathic pain.
Topics: Adrenergic alpha-2 Receptor Antagonists; Analgesics; Analysis of Variance; Animals; Clonidine; Cytok | 2011 |
The antinociceptive activity of intrathecally administered amiloride and its interactions with morphine and clonidine in rats.
Topics: Amiloride; Analgesics; Animals; Area Under Curve; Blood Pressure; Clonidine; Dose-Response Relations | 2012 |
Intrathecal clonidine in the neonatal rat: dose-dependent analgesia and evaluation of spinal apoptosis and toxicity.
Topics: Age Factors; Analgesics; Animals; Animals, Newborn; Apoptosis; Behavior, Animal; Carrageenan; Clonid | 2012 |
Ankle joint mobilization affects postoperative pain through peripheral and central adenosine A1 receptors.
Topics: Adenosine; Analysis of Variance; Animals; Ankle Joint; Caffeine; Clonidine; Disease Models, Animal; | 2013 |
Dissociated modulation of conditioned place-preference and mechanical hypersensitivity by a TRPA1 channel antagonist in peripheral neuropathy.
Topics: Acetanilides; Adrenergic alpha-2 Receptor Agonists; Animals; Clonidine; Conditioning, Psychological; | 2013 |
Stereo-selective inhibition of spinal morphine tolerance and hyperalgesia by an ultra-low dose of the alpha-2-adrenoceptor antagonist efaroxan.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Antagonists; Analgesics; Animals; Benzofurans | 2013 |
Intrathecal clonidine decreases spinal nitric oxide release in a rat model of complete Freund's adjuvant induced inflammatory pain.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Clonidine; Enzyme Inhibitors; Freu | 2002 |
Enhanced reduction in hyperalgesia by combined administration of clonidine and TENS.
Topics: Analgesics; Animals; Carrageenan; Clonidine; Combined Modality Therapy; Hyperalgesia; Inflammation; | 2002 |
Comparison of the visceral antinociceptive effects of spinally administered MPV-2426 (fadolmidine) and clonidine in the rat.
Topics: Adrenergic alpha-Agonists; Analgesics; Anesthesia; Animals; Clonidine; Colitis; Colon; Dose-Response | 2003 |
Anti-parkinsonian agents procyclidine and ethopropazine alleviate thermal hyperalgesia in neuropathic rats.
Topics: Adrenergic alpha-Agonists; Animals; Antiparkinson Agents; Clonidine; Constriction, Pathologic; Dose- | 2003 |
Antihyperalgesic and side effects of intrathecal clonidine and tizanidine in a rat model of neuropathic pain.
Topics: Adrenergic alpha-Agonists; Analgesics; Animals; Behavior, Animal; Blood Pressure; Bradycardia; Cloni | 2003 |
Perioperative administration of the alpha2-adrenoceptor agonist clonidine at the site of nerve injury reduces the development of mechanical hypersensitivity and modulates local cytokine expression.
Topics: Adrenergic alpha-Agonists; Animals; Behavior, Animal; Clonidine; Cytokines; Drug Combinations; Hyper | 2003 |
Spinal adenosine receptor activation reduces hypersensitivity after surgery by a different mechanism than after nerve injury.
Topics: Animals; Clonidine; Dose-Response Relationship, Drug; Hyperalgesia; Male; Pain Threshold; Postoperat | 2004 |
Mechanisms of analgesic action of neurotropin on chronic pain in adjuvant-induced arthritic rat: roles of descending noradrenergic and serotonergic systems.
Topics: Administration, Oral; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Analges | 2005 |
Alpha2-adrenoceptor stimulation transforms immune responses in neuritis and blocks neuritis-induced pain.
Topics: Adrenergic alpha-Agonists; Animals; Antibody Formation; Clonidine; Cytokines; Hyperalgesia; Leukocyt | 2005 |
Hyperexcitability of axotomized and neighboring unaxotomized sensory neurons is reduced days after perineural clonidine at the site of injury.
Topics: Action Potentials; Animals; Axotomy; Clonidine; Ganglia, Spinal; Hyperalgesia; Male; Membrane Potent | 2005 |
Clonidine maintains intrathecal self-administration in rats following spinal nerve ligation.
Topics: Analgesics; Animals; Clonidine; Hyperalgesia; Injections, Spinal; Male; Neuralgia; Pain Measurement; | 2006 |
The contribution of alpha-1 and alpha-2 adrenoceptors in peripheral imidazoline and adrenoceptor agonist-induced nociception.
Topics: Adrenergic alpha-Agonists; Agmatine; Analgesics; Animals; Clonidine; Dose-Response Relationship, Dru | 2006 |
Clonidine depresses LTP of C-fiber evoked field potentials in spinal dorsal horn via NO-cGMP pathway.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Affer | 2006 |
Antinociception mediated by alpha(2)-adrenergic activation involves increasing tumor necrosis factor alpha (TNFalpha) expression and restoring TNFalpha and alpha(2)-adrenergic inhibition of norepinephrine release.
Topics: Adrenergic alpha-Agonists; Analysis of Variance; Animals; Brimonidine Tartrate; Clonidine; Dose-Resp | 2007 |
Transient allodynia pain models in mice for early assessment of analgesic activity.
Topics: Adrenergic alpha-Antagonists; Amines; Amitriptyline; Analgesics; Animals; Clonidine; Cyclohexanecarb | 2008 |
Antinociceptive synergistic interaction between clonidine and ouabain on thermal nociceptive tests in the rat.
Topics: Analgesics; Animals; Behavior, Animal; Clonidine; Disease Models, Animal; Dose-Response Relationship | 2007 |
The involvement of peripheral alpha 2-adrenoceptors in the antihyperalgesic effect of oxcarbazepine in a rat model of inflammatory pain.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Carbamazepine; Clonidine; Disease Models, Animal; Dos | 2007 |
Peri-administration of clonidine or MK801 delays but does not prevent the development of mechanical hyperalgesia in a model of mononeuropathy in the rat.
Topics: Animals; Clonidine; Disease Models, Animal; Dizocilpine Maleate; Hyperalgesia; Injections, Subcutane | 1995 |
Pre-emptive administration of clonidine prevents development of hyperalgesia to mechanical stimuli in a model of mononeuropathy in the rat.
Topics: Analysis of Variance; Animals; Baclofen; Carbamazepine; Clonidine; Disease Models, Animal; Hyperalge | 1993 |
Multiple receptors involved in peripheral alpha 2, mu, and A1 antinociception, tolerance, and withdrawal.
Topics: Adenosine; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagon | 1997 |
Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain.
Topics: Analgesics; Analgesics, Opioid; Animals; Calcium Channel Blockers; Calcium Channels, N-Type; Clonidi | 2000 |
Brain-derived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent pain.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brain; Chronic Disease; Clonidine; | 2000 |
The mechanical antihyperalgesic effect of intrathecally administered MPV-2426, a novel alpha2 -adrenoceptor agonist, in a rat model of postoperative pain.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Clonidine; Dexmedetomidine | 2000 |
Moxonidine, a selective imidazoline-alpha2 -adrenergic receptor agonist, produces spinal synergistic antihyperalgesia with morphine in nerve-injured mice.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Analgesics; Animals; Clonidine; Dru | 2000 |
Systemic tizanidine hydrochloride (Zanaflex) relieves thermal hyperalgesia in rats with an experimental mononeuropathy.
Topics: Adrenergic alpha-Agonists; Animals; Clonidine; Disease Models, Animal; Hot Temperature; Hyperalgesia | 2001 |
Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKC gamma mutant mice.
Topics: Analgesics; Analgesics, Opioid; Animals; Clonidine; Drug Tolerance; Hyperalgesia; Isoenzymes; Male; | 2001 |
Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain.
Topics: Administration, Cutaneous; Adult; Clonidine; Female; Humans; Hyperalgesia; Norepinephrine; Pain; Phe | 1991 |
Spinal opioid analgesic effects are enhanced in a model of unilateral inflammation/hyperalgesia: possible involvement of noradrenergic mechanisms.
Topics: Adrenergic alpha-Antagonists; Animals; Carrageenan; Clonidine; Enkephalins; Hyperalgesia; Inflammati | 1991 |